A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
NCT00420992
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subject is 21 years of age or older
- Subject is either not of childbearing potential OR subject must use an acceptable method of birth control if of childbearing potential
- Negative pregnancy test if female of childbearing potential
- Subject is in general good health
- Subject required treatment of joint pain within the last 90 days
- Subject has primary diagnosis of osteoarthritis (OA) of the hip or knee
- Subject has a documented history of allergic reaction or intolerance to morphine or
other opioids
- Subject is pregnant or breast-feeding
- Subject is receiving systemic chemotherapy
- Subject has a history of drug abuse/dependence/misuse or alcohol abuse/dependence
- Subject has history of major depressive disorder not controlled with medication
- Subject has any chronic pain syndrome (i.e., fibromyalgia) that may interfere with the
symptoms of OA
- Subject has active gastrointestinal disease, with the exception of gastroesophageal
reflux disease (GERD)
- Subject has a documented history of rheumatoid arthritis, uncontrolled inflammatory
arthritis or non-steroidal anti-inflammatory drug (NSAID)-dependent inflammatory
arthritis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Mobile, Alabama
- Peoria, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Anaheim, California
- Anaheim, California
- Anaheim, California
- Buena Park, California
- Burbank, California
- Fair Oaks, California
- Hawaiian Gardens, California
- Irvine, California
- La Jolla, California
- La Jolla, California
- Pico Rivera, California
- Santa Monica, California
- Upland, California
- Denver, Colorado
- Stamford, Connecticut
- Trumbull, Connecticut
- Hallandale Beach, Florida
- Hialeah, Florida
- Jacksonville, Florida
- Jupiter, Florida
- Kissimmee, Florida
- Largo, Florida
- Merritt Island, Florida
- Ormond Beach, Florida
- Pembroke Pines, Florida
- Port Orange, Florida
- Tampa, Florida
- Weston, Florida
- Blue Ridge, Georgia
- Decatur, Georgia
- Marietta, Georgia
- Marietta, Georgia
- Boise, Idaho
- Peoria, Illinois
- Evansville, Indiana
- Newburgh, Indiana
- Overland Park, Kansas
- Mandeville, Louisiana
- New Orleans, Louisiana
- Towson, Maryland
- Fall River, Massachusetts
- No Dartmouth, Massachusetts
- Springfield, Massachusetts
- Saginaw, Michigan
- St. Louis, Missouri
- Henderson, Nevada
- Las Vegas, Nevada
- Voorhees, New Jersey
- Mount Vernon, New York
- Charlotte, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Cincinnati, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Allentown, Pennsylvania
- Bensalem, Pennsylvania
- Duncansville, Pennsylvania
- Fleetwood, Pennsylvania
- Souderton, Pennsylvania
- Tipton, Pennsylvania
- Clarksville, Tennessee
- Cordova, Tennessee
- Hendersonville, Tennessee
- Memphis, Tennessee
- Milan, Tennessee
- Austin, Texas
- DeSoto, Texas
- Killeen, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Roanoke, Virginia
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee | |||
Official Title ICMJE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee | |||
Brief Summary | The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period. | |||
Detailed Description | The primary objective of this study is to evaluate the efficacy of ALO-01 compared with placebo for the treatment of chronic moderate to severe pain (focusing on osteoarthritis of the hip or knee) as measured by mean change in diary Brief Pain Inventory (BPI) score of average pain (daily scores of average pain averaged over 7 days) from randomization to 12 weeks following randomization. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Setnik B, Pixton GC, Webster LR. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials. Curr Med Res Opin. 2016;32(3):563-72. doi: 10.1185/03007995.2015.1131153. Epub 2016 Jan 26. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 547 | |||
Original Enrollment ICMJE | 400 | |||
Actual Study Completion Date ICMJE | November 2007 | |||
Actual Primary Completion Date | November 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 21 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00420992 | |||
Other Study ID Numbers ICMJE | ALO-KNT-301 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2013 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |